.jpg "AxoGen (NASDAQ: AXGN)")
Today, the SVP Sales of AxoGen (NASDAQ: AXGN), Shawn Mccarrey, sold shares of AXGN for $434.7K.
Following Shawn Mccarrey’s last AXGN Sell transaction on August 30, 2013, the stock climbed by 39.2%.
See today’s analyst top recommended stocks >>
Based on AxoGen’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $17.26 million and GAAP net loss of $5.64 million. In comparison, last year the company earned revenue of $12.24 million and had a GAAP net loss of $3.76 million. The Company has a Price to Book ratio of 70.2458. Currently, AxoGen has an average volume of 483.3K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $42.67, reflecting a 3.0% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provide products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity.
